TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.
Dr. Giloz-Ran, has a long record of leveraging strategic planning and problem solving to drive business growth. She is a Certified Public Accountant and holds a PhD in tax, accounting and finance from Ben- Gurion University in Israel, and previously, served as the Head of the Accounting Program at the Peres Academic Center’s School of Business. Dr. Giloz-Ran has served as an external director in several public companies, including “Blue Square Real Estate,” “Aran R&D,” “Oversiz”, “Suny”, and “Kamada” and is the former chairperson of the board of directors of Tamir Fishman, a leading Israeli venture capital fund.
Dr. Giloz-Ran has also served as visiting scholar at the New York University Stern School of Business and held the position of visiting assistant professor of finance at the Yeshiva University School of Business. Dr. Giloz-Ran is currently a lecturer in the department of economics and accounting at Bar Ilan University in Israel.
Eran Ballan, Esq., brings exceptional management experience at large and complex corporate entities in international markets. Mr. Ballan served as Partner, and Head of the biotech department at Naschitz Brandes Amir, one of the largest law firms in Israel. Mr. Ballan holds an LL. B degree from Essex University, UK, and an LL.M degree from New York University, Faculty of Law.
Mr. Ballan serves as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel. Mr. Ballan brings a deep technical understanding in forming and executing cross-border corporate strategy and access to capital markets.
“Estery and Eran are exceptional additions to our board,” said Cannabics Pharmaceuticals’ CEO, Mr. Eyal Barad. “The experience and expertise they bring as entrepreneurs and corporate leaders is incredibly valuable in shaping and guiding the current direction of the company. These nominations will help strengthen our corporate governance where we seek to adhere to Nasdaq and NYSE standards. We believe our common energies and professionalism will elevate the delivery of our unique platform to market.”
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. For example, we are using forward-looking statements when we discuss the belief that the common energy between us and our new directors and our new directors’ professionalism will elevate the delivery of our unique platform to market, or when we discuss that these nominations will help strengthen our corporate governance. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.